Navigation Links
Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Date:8/31/2007

eing investigated to address LDL-C, HDL-C and triglycerides simultaneously in a single pill, which could improve convenience and lipid outcomes.

Abbott will continue executing the clinical trial program and be responsible for regulatory registration of the new combination therapy. AstraZeneca will hold the New Drug Application. Following successful completion of the clinical program, a regulatory application for the new combination therapy is targeted for submission in 2009. This collaboration relates to the US market.

About ABT-335

ABT-335 is a next-generation fenofibrate in clinical development for abnormal lipids in the bloodstream, including cholesterol and triglycerides. In addition, based on the positive results from ABT-335's clinical trial program, Abbott plans to file ABT-335 as a monotherapy (as an adjunct to diet) by the end of 2007. Abbott is currently evaluating ABT-335 as a

co-administered therapy with other on-market statins, including CRESTOR, and expects to present data from the clinical trials in the first half of 2008.

About CRESTOR(R)

CRESTOR (rosuvastatin calcium) is a once-daily, lipid-lowering agent prescription medication for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. It is a member of the statin (HMG-CoA reductase inhibitors) class of drug therapy. CRESTOR has not been determined to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is 10 mg. However, initiation of therapy with 5 mg once daily should be considered for patients requiring less aggressive LDL-C reductions or who have predisposing factors for myopathy, and for special populations such as patients taking cyclosporine, Asian patients, and patients with severe renal insufficiency. For patients with marked hypercholestero
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
9. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
10. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
11. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
(Date:5/22/2015)... R.I. , May 22, 2015 ... once-daily central nervous system stimulant indicated for the ... to patients beginning Summer 2015. ... XR received approval from the U.S. Food and ... is an extended-release formulation of methylphenidate capsule with ...
(Date:5/22/2015)... Calif. , May 22, 2015 AcelRx ... company focused on the development and commercialization of innovative ... today announced that interim chief executive officer Howie ... Conference and chief financial officer Tim Morris ... Details of the two presentations are as follows: ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
... 6, 2011 Endologix, Inc. (Nasdaq: ELGX ... announced today that John McDermott, President and Chief Executive ... of America Merrill Lynch Health Care Conference in Las ... ConferenceDate:Tuesday, May 10, 2011Time:3:40 p.m. PTAn audio Web cast ...
... N.M., May 6, 2011 Qforma, the leading provider of ... health sciences industry, announced today the appointment of Mark Spiers ... President and CEO of Wolters Kluwer Pharma Solutions. ... leader in the pharmaceutical industry, to our Board," said Kelly ...
Cached Medicine Technology:Qforma Appoints New Member to Board of Directors 2
(Date:5/23/2015)... On Saturday, May 23, 2015, over 100 volunteers are ... City exactly five years to the day after the disastrous ... large fire tore through the Branches United Methodist Church and ... middle of the night as neighbors, staff and Branches' children ... though it is suspected that the fire began accidentally. Branches ...
(Date:5/23/2015)... Dr. David Benvenuti, an experienced plastic surgeon ... new article to his website that takes an ... explained in the fascinating blog, he has recently had ... , Known as “gauging,” the technique involves placing larger and ... said will eventually stretch the holes out to incredible sizes. ...
(Date:5/23/2015)... 23, 2015 On Wednesday, May 20, ... company has been the target of a sophisticated cyberattack,” ... the company’s ongoing Information Technology (IT) security efforts in ... , The most notable attack on health insurers was ... the nation’s second largest health insurer, revealed that they ...
(Date:5/23/2015)... Manufacturers are now required to produce water heaters with a ... the field agree that the regulation is aimed at manufacturers, ... what miles per gallon is to your car. The higher ... HSPF score has been raised to 8.2, technology has since ... 12. Indeed, the regulation was welcomed by environmentalist, and members ...
(Date:5/23/2015)... 2015 Javon Bea Mercy Health ... Medicine and Rehabilitation Center, 557 N. Washington St., Janesville, ... 1-July 20, 5:30-6:30 pm. , The 8-week clinic is ... Finke, RN, BSN, who will offer training that encompasses ... running mechanics and show selection and weekly training plans. ...
Breaking Medicine News(10 mins):Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
... shows it reduces risk of death, recurrence , TUESDAY, Dec. ... can help lower the risk of death and cancer recurrence ... What,s more, the association between soy and a reduced risk ... cancers and women taking tamoxifen, according to the study published ...
... , NEW YORK, Dec. 8 ... is available in its catalogue: , Japanese ... , http://www.reportlinker.com/p0166832/Japanese-Market-for-Dental-Implants-and-Final-Abutments-2009.html , The Japanese market ... affected by the economic recession beginning in 2008, leading ...
... million shot in the arm to the largest grant the ... stimulus funding, provided by the American Recovery and Reinvestment Act ... by MCG: one developing animal models to study diabetes complications, ... procedures to scientists studying a disease that can wreak lifelong ...
... license approvals for diabetics should be re-evaluated, expert ... who keep their blood sugar tightly controlled run the ... sugar, Canadian researchers report. , Controlling blood sugar is ... under control, diabetics can ward off many of the ...
... , , SAN FRANCISCO, Dec. 8 ... in the Bay Area, announced a $1 million donation from ... was made at Tipping Point Community,s Third Annual Awards Breakfast ... , In the Bay Area, one-quarter of families ...
... ... alternative to hip replacement surgery in patients 20 – 60 years of age. , ... (PRWEB) December 8, 2009 -- Dr. ... hip offers patients a less invasive alternative to hip replacement., , ,Using non-embryonic stem cells ...
Cached Medicine News:Health News:Soy Beneficial for Breast Cancer Survivors: Study 2Health News:Soy Beneficial for Breast Cancer Survivors: Study 3Health News:Reportlinker Adds Japanese Market for Dental Implants and Final Abutments 2009 2Health News:Reportlinker Adds Japanese Market for Dental Implants and Final Abutments 2009 3Health News:Reportlinker Adds Japanese Market for Dental Implants and Final Abutments 2009 4Health News:Reportlinker Adds Japanese Market for Dental Implants and Final Abutments 2009 5Health News:Reportlinker Adds Japanese Market for Dental Implants and Final Abutments 2009 6Health News:Recovery Act dollars are stimulating research at the Medical College of Georgia 2Health News:Recovery Act dollars are stimulating research at the Medical College of Georgia 3Health News:Too-Strict Blood Sugar Control May Lead to Car Crashes 2Health News:Too-Strict Blood Sugar Control May Lead to Car Crashes 3Health News:Tipping Point Community Announces $1 Million Gift at Third Annual Awards Breakfast 2Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 2Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 3Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: